Companies: 10,795·Total market cap: $144.5T
Altamira Therapeutics Ltd.

Altamira Therapeutics Ltd.

CYTONASDAQHealthcare
$0.30
+$0.30(+100.00%)
Market Cap$1133556
P/E Ratio
52W High$0.4158
52W Low$0.3

Altamira Therapeutics Ltd. (CYTO) Stock Ownership

Latest 13F position summary is not yet available — breakdown and tables fill in after filings publish (typically ~45 days after quarter end).

SEC 13F · FMP · CYTO · as of —

Ownership Breakdown

Institutional data for this period is not yet available. SEC Form 13F filings are typically published 45 days after quarter end.

No institutional data available for this period.

Insider Buying vs Selling

CYTO insider trading · insider activity

Source: SEC Form 4

Recent Insider Transactions

Showing 10 most recent · Common Stock only

No recent insider transactions reported.

Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.

About institutional & insider ownership

Altamira Therapeutics Ltd. (CYTO) is primarily owned by institutional investors, who hold approximately — of total shares outstanding. Company insiders own approximately —, while retail and public investors account for the remaining —.

A total of 0 institutional investors currently hold CYTO stock, with a combined institutional value of approximately $0 as of the most recent 13F filing period.

Frequently asked questions

CYTO ownership

Altamira Therapeutics Ltd. (CYTO) is primarily owned by institutional investors, who hold approximately — of shares. The largest shareholder is — with a — stake. Company insiders hold —. Data sourced from SEC Form 13F as of —.

who owns CYTO stockCYTO ownership structureSEC Form 13F institutional holdingsCYTO float vs institutions
Source: FMP · SEC Form 13F · SEC Form 4As of